Attenuated reassortant vaccine candidate strain of reduced pathogenicity relative to the wild type A/California/4/2009 virus. Contains a high concentration of viral antigens as well as some egg proteins (Allantoic fluid). Reassortant virus includes genetic components of the H1N1 influenza pandemic swine flu in a culture-adapted virus that has been selected for its qualities as a vaccine-producing strain.
Inactivation:
Gamma radiation inactivation. The effectiveness of inactivation is shown when there is no detection of growth in two blind passages under standard cell culture conditions (MDCK cells). No live virus is detected by either CPE or HA Assay. Result: No growth detected.
Storage and Stability:
Aliquot to avoid repeated freezing and thawing and store at -70 degrees C. Aliquots are stable for 6 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.